Please assess the completion status of the following clinical trial:

Trial Title: Injectable Diclofenac for the Prevention of Post-operative Dental Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Out-patients of either gender.~2. Patients aged ≥ 18 to ≤ 65 years old.~3. Subjects able and willing to give their written consent prior to inclusion in the study.~4. Female subjects of childbearing potential must (1) have a negative urine pregnancy test at the inclusion visit, (2) be using an appropriate method of contraception according to the definition of Note of ICH M3 Guideline (implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner), and (3) be willing to continue using the contraceptive method throughout the entire study period.~5. Subjects must (1) be able to comprehend the full nature and purpose of the study, including possible risks and side effects, (2) fully co-operate with the Investigator, (3) comply with the requirements of the entire study.~6. Patients undergoing surgical extraction of a single, fully or partially impacted mandibular 3rd molar requiring bone removal.~Exclusion Criteria:~General~1. Patients refusing to give written informed consent.~2. Patients not able to understand the purposes of the study or not willing to return for the control visits.~3. Patients with major psychiatric disorders that, in the investigator's opinion, could compromise study participation.~4. Patients enrolled in any clinical trial in the previous 3 months.~5. Employees of the study centre with direct involvement in the proposed study or other studies under the direction of the main investigator or study centre, as well as family members of the employees or investigator.~6. Pregnant or breast-feeding women.~7. Alcohol or drug abuse in the previous 12 months.~8. Clinically significant or unstable concomitant disease whose sequelae might interfere with the study evaluation parameters.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Diclofenac sodium 5 mg/mL (Type: EXPERIMENTAL): None
- Diclofenac sodium 12.5 mg/mL (Type: EXPERIMENTAL): None
- Diclofenac sodium 25 mg/mL (Type: EXPERIMENTAL): None
- Diclofenac sodium 50 mg/mL (Type: EXPERIMENTAL): None
- Placebo 1 mL (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).